Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L, Lissitchkov T, Dobaczewski G, Klukowska A, Komrska V, Zimmermann R, Auerswald G, Engl W, Abbühl B, Pavlova BG, Ehrlich HJ. Nemes L, et al. Among authors: ehrlich hj. Acta Haematol. 2008;119(2):89-97. doi: 10.1159/000118628. Epub 2008 Feb 28. Acta Haematol. 2008. PMID: 18305381 Clinical Trial.
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ. Björkander J, et al. Among authors: ehrlich hj. Vox Sang. 2006 May;90(4):286-93. doi: 10.1111/j.1423-0410.2006.00764.x. Vox Sang. 2006. PMID: 16635071 Clinical Trial.
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, Wasserman RL, Pavlova BG, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich HJ; US-PID-IGIV 10% -Study Group10. Church JA, et al. Among authors: ehrlich hj. J Clin Immunol. 2006 Jul;26(4):388-95. doi: 10.1007/s10875-006-9025-3. Epub 2006 May 17. J Clin Immunol. 2006. PMID: 16705486 Clinical Trial.
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. Ehrlich HJ, et al. N Engl J Med. 2008 Jun 12;358(24):2573-84. doi: 10.1056/NEJMoa073121. N Engl J Med. 2008. PMID: 18550874 Free article. Clinical Trial.
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, Harmacek P, Krammer M, Barrett PN, Ehrlich HJ; FSME-IMMUN study group. Loew-Baselli A, et al. Among authors: ehrlich hj. Vaccine. 2006 Jun 12;24(24):5256-63. doi: 10.1016/j.vaccine.2006.03.061. Epub 2006 Apr 3. Vaccine. 2006. PMID: 16624457 Clinical Trial.
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ. Tambyah PA, et al. Among authors: ehrlich hj. Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22080174 Clinical Trial.
103 results